Sage Rhino Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

Sage Rhino Capital’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-453	Closed	-$220K	–	298
2025 Q1	$220K	Buy	+453	New	+$211K	0.05%	219
2024 Q4	–	Sell	-520	Closed	-$242K	–	296
2024 Q3	$242K	Sell	520 -26	-5%	-$12.5K	0.05%	205
2024 Q2	$256K	Sell	546 -12	-2%	-$5.21K	0.06%	190
2024 Q1	$233K	Buy	558 +5	+0.9%	+$2.11K	0.06%	198
2023 Q4	$225K	Sell	553 -54	-9%	-$19.9K	0.06%	192
2023 Q3	$211K	Sell	607 -4	-0.7%	-$1.4K	0.06%	193
2023 Q2	$215K	Buy	+611	New	+$206K	0.06%	193
2022 Q3	–	Sell	-934	Closed	-$263K	–	203
2022 Q2	$263K	Sell	934 -549	-37%	-$147K	0.1%	158
2022 Q1	$387K	Sell	1,483 -88	-6%	-$20.9K	0.12%	144
2021 Q4	$345K	Buy	1,571 +27	+2%	+$5.25K	0.1%	148
2021 Q3	$280K	Buy	1,544 +23	+2%	+$4.49K	0.09%	155
2021 Q2	$307K	Buy	1,521 +8	+0.5%	+$1.67K	0.09%	150
2021 Q1	$325K	Buy	1,513 +265	+21%	+$58.2K	0.11%	132
2020 Q4	$295K	Buy	1,248 +116	+10%	+$26.6K	0.12%	133
2020 Q3	$308K	Buy	1,132 +91	+9%	+$25.1K	0.15%	113
2020 Q2	$302K	Buy	1,041 +27	+3%	+$7.32K	0.16%	109
2020 Q1	$241K	Sell	1,014 -6	-0.6%	-$1.38K	0.17%	106
2019 Q4	$234K	Buy	+1,020	New	+$206K	0.13%	130

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Sage Rhino Capital's VRTX Position: Q2 2025 in Review

Sage Rhino Capital sold out of Vertex Pharmaceuticals (VRTX) in Q2 2025, closing a stake of 453 shares — an estimated $220K sold.

Sage Rhino Capital first reported a position in VRTX in Q4 2019 and held it in 18 quarters. The position peaked at $387K in Q1 2022. 1,563 funds tracked by Wall St. Rank hold VRTX as of Q2 2025.

Sage Rhino Capital reported no remaining Vertex Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Sage Rhino Capital sold 453 Vertex Pharmaceuticals shares in Q2 2025, an estimated $220K.
Sage Rhino Capital first reported a position in Vertex Pharmaceuticals in Q4 2019 and held it in 18 quarters.
Sage Rhino Capital's Vertex Pharmaceuticals position peaked at $387K in Q1 2022.
1,563 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2025.

Based on Sage Rhino Capital's 13F filing for Q2 2025, filed 17 Jul 2025.